The popularity of copyright’s blockbuster initially fueled a surge for major pharmaceutical companies, but recent changes present a murky picture for shareholders. Off-patent versions are reducing earnings, and persistent legal battles add further risk to the equation. While some companies could still see gains from related offerings, the genera… Read More